Alterations in serotype-specific B cell responses to the 13-valent pneumococcal conjugate vaccine in aging HIV-infected adults

• Published in: Vaccine Vol. 34; no. 4; pp. 451 - 457
• Main Authors: Ohtola, Jennifer A., Khaskhely, Noor M., Saul-Mcbeth, Jessica L., Iyer, Anita S., Leggat, David J., Khuder, Sadik A., Westerink, M.A. Julie
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 20.01.2016; Elsevier Limited
• Subjects: Aging; Allergy and Immunology; Anti-Retroviral Agents - therapeutic use; Antibodies, Bacterial - blood; Antigens; Antiretroviral agents; B cells; B-Lymphocyte Subsets - cytology; B-Lymphocyte Subsets - immunology; complement; cyclophilins; elderly; Female; Health risks; HIV; HIV infection; HIV infections; HIV Infections - drug therapy; HIV Infections - immunology; Human immunodeficiency virus; Humans; Immunization; Immunology; Infections; Male; Middle Aged; phenotype; Pneumococcal conjugate vaccine; Pneumococcal Infections - prevention & control; Pneumococcal polysaccharide vaccine; Pneumococcal Vaccines - administration & dosage; polysaccharides; receptors; risk; Software; Streptococcus pneumoniae; Studies; Transmembrane Activator and CAML Interactor Protein - metabolism; tumor necrosis factors; vaccination; Vaccines; Vaccines, Conjugate - administration & dosage; Variance analysis; OPA; TNFR; Pneumococcal conjugate vaccine; PCV; ART; CBC; IQR; B cells; Streptococcus pneumoniae; BAFF-R; CD4; PPS; HIV; TACI; Pneumococcal polysaccharide vaccine; ANOVA; ACIP; PPV; Aging; HIV infection; Ig; antiretroviral therapy; interquartile range; CD4 + T cells/μl; analysis of variance; calcium-modulating cyclophilin ligand interactor; B cell-activating factor receptor; 23-valent pneumococcal polysaccharide vaccine; immunoglobulin; Advisory Committee on Immunization Practices; complete blood count; 13-valent pneumococcal conjugate vaccine; opsonophagocytic killing assay; human immunodeficiency virus; pneumococcal polysaccharide; tumor necrosis superfamily receptor
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2015.12.013

Advanced age and human immunodeficiency virus (HIV) infection are associated with increased pneumococcal disease risk. The impact of these factors on cellular responses to vaccination is unknown. HIV-infected (HIV+) individuals 50–65 years old with CD4+ Tcells/μl (CD4) >200 on antiretroviral therapy (ART) ≥1 year received either the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine (PCV/PPV) or PPV only. HIV-uninfected (HIV−) controls received PCV/PPV. Phenotype distribution and surface expression of complement receptor CD21 and tumor necrosis factor superfamily receptors (TNFRs) were compared on serotype-specific B cells postvaccination. Postvaccination serotype-specific B cell percentages were significantly lower in HIV+ PCV/PPV compared to PPV groups, but similar between HIV+ or HIV− PCV/PPV groups. Transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI)+ serotype-specific B cell percentages were significantly decreased in HIV+ PCV/PPV compared to PPV groups. CD21+ serotype-specific B cells were significantly higher in HIV− compared to HIV+ PCV/PPV groups. An initial dose of PCV reduced the frequency, but not phenotype distribution, of serotype-specific B cells and also lowered TACI expression in aging HIV+ subjects postvaccination with PPV. These findings suggest that PCV does not enhance cellular responses to revaccination with PPV.